Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 3Phase 4 2Phase 1/2 2Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Non-Small-Cell Lung 439Neoplasms 364Breast Neoplasms 261Colorectal Neoplasms 245Neoplasm Metastasis 217Melanoma 210Leukemia, Myeloid, Acute 188Multiple Myeloma 187Pancreatic Neoplasms 183Ovarian Neoplasms 181Recurrence 175Prostatic Neoplasms 161Lymphoma, Non-Hodgkin 142Stomach Neoplasms 133Squamous Cell Carcinoma of Head and Neck 128Lung Neoplasms 126Lymphoma 121Carcinoma, Hepatocellular 117Carcinoma, Renal Cell 102Triple Negative Breast Neoplasms 100Leukemia, Lymphocytic, Chronic, B-Cell 99Glioblastoma 98Advanced Solid Tumor 94Leukemia 93Small Cell Lung Carcinoma 91Lymphoma, Large B-Cell, Diffuse 90Head and Neck Neoplasms 87Advanced Solid Tumors 85Endometrial Neoplasms 81Myelodysplastic Syndromes 78

Interventions

Midazolam 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × Prostate Cancer Metastatic × Clear all
NCT03436485 2025-07-22

CYPIDES

Orion Corporation, Orion Pharma

Phase 1/2 Active not recruiting
204 enrolled
Genitourinary

Prostate Cancer Metastatic

NCT01595087 2014-11-14

A Phase I/II Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)

DexTech Medical AB

Phase 1/2 Completed
28 enrolled
Genitourinary

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡